Russell Investments Group
NTLA icon

Russell Investments Group’s Intellia Therapeutics NTLA Stock Holding History

Russell Investments Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17M Buy
128,253
+68,821
+116% +$963K ﹤0.01% 2045
2026
Q1 		$762K Buy
59,432
+49,833
+519% +$635K ﹤0.01% 2340
2025
Q4 		$86.3K Sell
9,599
-1,709
-15% -$23.5K ﹤0.01% 3095
2025
Q3 		$195K Buy
11,308
+9,973
+747% +$123K ﹤0.01% 2823
2025
Q2 		$12.5K Sell
1,335
-7,016
-84% -$57.6K ﹤0.01% 3287
2025
Q1 		$59.4K Sell
8,351
-109,064
-93% -$1.1M ﹤0.01% 2869
2024
Q4 		$1.37M Sell
117,415
-81,095
-41% -$1.27M ﹤0.01% 1850
2024
Q3 		$4.08M Buy
198,510
+47,932
+32% +$1.11M 0.01% 1293
2024
Q2 		$3.37M Buy
150,578
+40,335
+37% +$960K 0.01% 1356
2024
Q1 		$3.03M Sell
110,243
-961
-0.9% -$26.7K ﹤0.01% 1420
2023
Q4 		$3.39M Sell
111,204
-16,063
-13% -$462K 0.01% 1323
2023
Q3 		$4.02M Buy
127,267
+27,730
+28% +$1.08M 0.01% 1189
2023
Q2 		$4.06M Sell
99,537
-10,829
-10% -$439K 0.01% 1185
2023
Q1 		$4.11M Buy
110,366
+33,968
+44% +$1.33M 0.01% 1193
2022
Q4 		$2.67M Sell
76,398
-5,969
-7% -$284K 0.01% 1412
2022
Q3 		$4.61M Sell
82,367
-31,359
-28% -$1.95M 0.01% 1093
2022
Q2 		$5.88M Buy
113,726
+2,306
+2% +$117K 0.01% 1020
2022
Q1 		$8.1M Buy
111,420
+34,526
+45% +$2.93M 0.01% 919
2021
Q4 		$9.09M Buy
76,894
+43,763
+132% +$5.48M 0.01% 945
2021
Q3 		$4.44M Buy
33,131
+5,134
+18% +$777K 0.01% 1322
2021
Q2 		$4.53M Sell
27,997
-25,520
-48% -$1.99M 0.01% 1416
2021
Q1 		$4.29M Sell
53,517
-34,056
-39% -$2.29M 0.01% 1435
2020
Q4 		$4.77M Buy
+87,573
New +$3.18M 0.01% 1258
2017
Q2 		– Sell
-9,698
Closed -$137K – 3010
2017
Q1 		$137K Buy
+9,698
New +$130K ﹤0.01% 2777

Other funds holding NTLA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Russell Investments Group's NTLA Position: Q2 2026 in Review

Russell Investments Group increased its Intellia Therapeutics (NTLA) stake by 116% in Q2 2026, buying an estimated $963K and bringing the position to 128,253 shares worth $2.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2045.

Russell Investments Group first reported a position in NTLA in Q1 2017 and has held it in 24 quarters since. The position peaked at $9.09M in Q4 2021. 144 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Russell Investments Group held 128,253 shares of Intellia Therapeutics worth $2.17M as of Q2 2026.
  • Russell Investments Group bought 68,821 Intellia Therapeutics shares in Q2 2026, an estimated $963K.
  • Intellia Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2045 holding.
  • Russell Investments Group first reported a position in Intellia Therapeutics in Q1 2017 and has held it in 24 quarters since.
  • Russell Investments Group's Intellia Therapeutics position peaked at $9.09M in Q4 2021.
  • 144 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.